Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation

Current Opinion in Organ Transplantation

Volumn 18, Issue 4, 2013, Pages 463-469

  Campbell, Patricia ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antibody mediated rejection; heart; human leukocyte antigen antibodies; liver and intestine; lung

Indexed keywords

COMPLEMENT COMPONENT C1Q; GLUTATHIONE TRANSFERASE T1; HLA ANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G;

ACUTE GRAFT REJECTION; ARTERIAL CIRCULATION; BLOOD GROUP ABO INCOMPATIBILITY; CHRONIC GRAFT REJECTION; ENDOTHELIUM CELL; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEPATITIS C; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MICROVASCULATURE; POST TREATMENT SURVIVAL; REVIEW; TISSUE INJURY;

BIOLOGICAL MARKERS; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INTESTINES; ISOANTIBODIES; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; TISSUE DONORS;

EID: 84880864460     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283636c71     Document Type: Review

References (68)

1. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95:19-47.
2. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6:2307-2315
3. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88:447-452
4. Morath C, Opelz G, Zeier M, Susal C. Kidney transplantation for high-risk sensitized patients: The 'Heidelberg algorithm'. Transplant Proc 2011; 43:801-804
5. Shakar SF, Lindenfeld J. Editorial commentary: 'all that glitters is not gold'. J Heart Lung Transplant 2012; 31:441-442
6. Nikaein A, El-Awar N, Hunt J, et al. Clinically irrelevant circulating human leukocyte antigen antibodies in the presence of ventricular assist devices. J Heart Lung Transplant 2012; 31:443-447
7. Arnaoutakis GJ, George TJ, Kilic A, et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: Update in a modern cohort. J Thorac Cardiovasc Surg 2011; 142:1236-1245
8. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, et al. Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86:1111-1115
9. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not beta2m-free heavy chainspecific HLA class I antibodies are predictive of graft failure. Transplantation 2009; 88:226-230
10. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72:849-858
11. Liu C, Wetter L, Pang S, et al. Cutoff values and data handling for solid-phase testing for antibodies to HLA: Effects on listing unacceptable antigens for thoracic organ transplantation. Hum Immunol 2012; 73:597-604
12. Wahrmann M, Hlavin G, Fischer G, et al. Modified solid-phase alloantibody detection for improved crossmatch prediction. Hum Immunol 2013; 74:32-40
13. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13:411-418
14. Lachmann N, Todorova K, Schulze H, Schonemann C. Systematic comparison of four cell-and Luminex-based methods for assessment of complementactivating HLA antibodies. Transplantation 2013; 95:694-700
15. Kaneku H. Annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl 2011; 311-318
16. Kushihata F, Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: Role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004; 78:995-1001
17. Schaub S, Scornik JC. High-tech detection of HLA antibodies and complement: Prospects and limitations. Am J Transplant 2008; 8:5-6
18. Watanabe J, Scornik JC. Measuring human complement activation by HLA antibodies. Arch Pathol Lab Med 2006; 130:368-373
19. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibodymediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32:98-105
20. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30:158-163
21. Weinstock C, Schnaidt M. The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 2013; 40:171-177
22. Hubscher S. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17:280-286
23. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12:2526-2531
24. Iacob S, Cicinnati VR, Dechene A, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int 2012; 32:1253-1261
25. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11:1868-1876
26. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11:500-510
27. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: Can C4d stains help in monitoring? Am J Transplant 2012; 12:171-182
28. Ali S, Ormsby A, Shah V, et al. Significance of complement split product C4d in ABO-compatible liver allograft: Diagnosing utility in acute antibody mediated rejection. Transpl Immunol 2012; 26:62-69
29. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12:1504-1510
30. Farmer DG, Venick RS, Colangelo J, et al. Pretransplant predictors of survival after intestinal transplantation: Analysis of a single-center experience of more than 100 transplants. Transplantation 2010; 90:1574-1580
31. Abu-Elmagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver. Am J Transplant 2012; 12:3047-3060
32. Tsai HL, Island ER, Chang JW, et al. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011; 92:709-715
33. Hawksworth JS, Rosen-Bronson S, Island E, et al. Successful isolated intestinal transplantation in sensitized recipients with the use of virtual crossmatching. Am J Transplant 2012; 12 (Suppl 4):S33-S42
34. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11:841-847
35. Saidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2:61-67
36. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13:954-960
37. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86:377-383
38. Campos EF, Tedesco-Silva H, Machado PG, et al. Posttransplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6:2316-2320
39. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94:172-177
40. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLAdirected antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80:1019-1025
41. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11:312-319
42. Ho EK, Vlad G, Vasilescu ER, et al. Pre and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72:5-10
43. Ho EK, Vasilescu ER, Vlad G, et al. HLA antibodies in pediatric heart transplantation. Pediatr Transplant 2011; 15:458-464
44. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18:1333-1342
45. Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: A 10 year experience in 441 patients. Chest 2013. [Epub ahead of print
46. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167
47. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93:41-46
48. Takenaka M, Subramanian V, Tiriveedhi V, et al. Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant 2012; 31:1214-1222
49. Hodges AM, Lyster H, McDermott A, et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donorspecific human leukocyte antigen antibody. Transplantation 2012; 93:650-656
50. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10:1812-1822
51. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15:42-48
52. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73:1226-1232
53. Hachem RR. Antibodies to human leukocyte antigens in lung transplantation. Clin Transpl 2011; 327-332
54. Brugiere O, Suberbielle C, Thabut G, et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay. Transplantation 2013; 95:761-765
55. Peltz M, Edwards LB, Jessen ME, et al. HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: Implications for donor lung allocation. J Heart Lung Transplant 2011; 30:426-434
56. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91:1036-1043
57. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71:886-892
58. Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant 2012; 12:2164-2171
59. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30:624-631
60. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transplant 2011; 17:779-788
61. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: Targets of antibodymediated rejection in heart transplantation. Transplantation 2011; 91:1153-1158
62. Tiriveedhi V, Angaswamy N, Brand D, et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to selfantigen leading to chronic lung allograft rejection. Clin Exp Immunol 2012; 167:158-168
63. Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95:755-760
64. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30:252-269
65. Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18:1154-1170
66. Gambetta K, Tambur A, Pahl E. Immune monitoring of pediatric heart transplant recipients through serial donor specific antibody testing: An initial experience and review of the literature. Prog Pediatr Cardiol 2011; 32:43-49
67. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7:576-585
68. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. Am J Transplant 2009; 9:2561-2570